Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Comment by QContinuum1on Sep 25, 2024 2:02pm
72 Views
Post# 36240653

RE:What to expect in this second half of 2024

RE:What to expect in this second half of 2024
alleyesonme wrote: Q1 CC transcript... best to offer on what could be expected...worth a run through....https://seekingalpha.com/article/4693474-medipharm-labs-corp-medif-q1-2024-earnings-call-transcript


A fantastic reminder.  But in general, it's, lots of growth expectations in the back half of 2024.  Q3 will tell that tale and if they were being forthright.  Given the apparent downtrend in sales in Canada, we will certainly need the substantial positive international growth that they speak of for the remainder of the calendar and FY for the topline and bottom line to continue to look good.  Without that, nobody is going to give this pig a second look and the SP will stay as is.

They have already (seemingly) missed the timelines with the additional Brazil approvals, so no idea what's going on there.
<< Previous
Bullboard Posts
Next >>